NCT05021835已完成3 期
ZEUS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 6,385
- 试验地点
- 2,059
- 主要终点
- Time to first occurrence of 3-point Major Adverse Cardiovascular Event (MACE), a composite endpoint consisting of: Cardiovascular (CV) death, non-fatal Myocardial Infarction (MI) and non-fatal stroke
研究概览
简要总结
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.
Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same.
Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine doctors cannot prescribe.
Participants will get the study medicine in a pre filled syringe. Participants will need to use the pre filled syringe to inject the study medicine into a skinfold once-monthly.
The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have blood and urine samples taken at most of the clinic visits.
Participants will have their heart examined using sound waves (echocardiography) and electrodes (electrocardiogram).
Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chronic kidney disease defined by one of the below:
- •Estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 15 and below 60 mL/min/1.73 m^2 (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation)
- •Urinary albumin-to-creatinine ratio (UACR) >= 200 milligrams per gram (mg/g) and eGFR >= 60 mL/min/1.73 m2 (using the CKD-EPI creatinine equation)
- •Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2 milligram per liter (mg/L)
- •Evidence of atherosclerotic cardiovascular disease (ASCVD) by one or more of the following:
- •a) Coronary heart disease defined as at least one of the following: i. Documented history of MI ii. Prior coronary revascularisation procedure iii. greater than or equal to 50% stenosis in major epicardial coronary artery documented by cardiac catheterisation or CT coronary angiography b) Cerebrovascular disease defined as at least one of the following: i. Prior stroke of atherosclerotic origin ii. Prior carotid artery revascularisation procedure iii. greater than or equal to 50% stenosis in carotid artery documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound.
- •c) Symptomatic peripheral artery disease (PAD) defined as at least one of the following: i. Intermittent claudication with an ankle-brachial index (ABI) below or equal to 0.90 at rest ii. Intermittent claudication with a greater than or equal to 50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound iii. Prior peripheral artery (excluding carotid) revascularisation procedure iv. Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g. trauma or osteomyelitis).
排除标准
- •Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.
- •Myocardial infarction, stroke, hospitalisation for unstable angina pectoris, or transient ischaemic attack within 60 days prior to randomisation (visit 2).
- •Planned coronary, carotid or peripheral artery revascularisation known on the day of randomisation (visit 2).
- •Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2).
研究组 & 干预措施
Placebo
Placebo Comparator
Participants will receive either placebo (Ziltivekimab B) or placebo (Ziltivekimab C) subcutaneously once monthly for up to 4 years.
干预措施: Placebo (Ziltivekimab C) (Drug)
Ziltivekimab
Experimental
Participants will receive Ziltivekimab B or Ziltivekimab C subcutaneously once monthly for up to 4 years.
干预措施: Ziltivekimab B (Drug)
Ziltivekimab
Experimental
Participants will receive Ziltivekimab B or Ziltivekimab C subcutaneously once monthly for up to 4 years.
干预措施: Ziltivekimab C (Drug)
Placebo
Placebo Comparator
Participants will receive either placebo (Ziltivekimab B) or placebo (Ziltivekimab C) subcutaneously once monthly for up to 4 years.
干预措施: Placebo (Ziltivekimab B) (Drug)
结局指标
主要结局
Time to first occurrence of 3-point Major Adverse Cardiovascular Event (MACE), a composite endpoint consisting of: Cardiovascular (CV) death, non-fatal Myocardial Infarction (MI) and non-fatal stroke
时间窗: From randomisation (month 0) to end-of-study (up to 48 months)
Months
次要结局
- Time to first occurrence of expanded MACE, a composite endpoint consisting of: CV death, non-fatal MI, non-fatal stroke and hospitalisation for unstable angina pectoris requiring urgent coronary revascularisation(From randomisation (month 0) to end-of-study (up to 48 months))
- Number of heart failure hospitalisations or urgent heart failure visits or CV deaths(From randomisation (month 0) to end-of-study (up to 48 months))
- Time to first occurrence of MI (fatal and non-fatal).(From randomisation (month 0) to end-of-study (up to 48 months).)
- Time to first occurrence of a 4-component kidney endpoint consisting of: onset of persistent at least 40% reduction in eGFR (CKD-EPI) compared with baseline, kidney failure(From randomisation (month 0) to end-of-study (up to 48 months).)
- Time to first occurrence of coronary revascularisation(From randomisation (month 0) to end-of-study (up to 48 months).)
- Change in Urinary Abumin-to-Ceatinine ratio (UACR).(From randomisation (month 0) to 2 years (24 months).)
- Change in eGFR (CKD-EPI))(From randomisation (month 0) to 2 years (24 months))
- Annual rate of change in eGFR (CKD-EPI) (total eGFR slope)(From randomisation (month 0) to end-of-study (up to 48 months).)
- Change in high-sensitivity C-reactive protein (hs-CRP)(From randomisation (month 0) to 2 years (24 months)
- Change in N-terminal-pro-brain natriuretic peptide ( NT-pro-BNP)(From randomisation (month 0) to 2 years (24 months))
- Change in left ventricular ejection fraction (LVEF)(From randomisation (month 0) to 2 years (24 months))
- Number of events of atrial fibrillation(From randomisation (month 0) to end-of-study (up to 48 months).)
- Change in haemoglobin(From randomisation (month 0) to 2 years (24 months))
- Number of hospitalisations with infection as primary cause or death due to infection.(From randomisation (month 0) to end-of-study (up to 48 months).)
- Change in Short Form 36 (SF-36) Physical Component Score (PCS)(From randomisation (month 0) to 2 years (24 months))
- Time to first occurrence of a composite kidney endpoint consisting of: CV death, onset of persistent atleast 40 percent (%) reduction in eGFR (CKD-epidemiology collaboration [CKD-EPI]) compared with baseline, kidney failure(From randomisation (month 0) to end-of-study (up to 48 months))
- Time to occurrence of all-cause mortality(From randomisation (month 0) to end-of-study (up to 48 months))
- Time to first occurrence of each of the individual components of the expanded MACE endpoint and the kidney composite endpoint.(From randomisation (month 0) to end-of-study (up to 48 months).)
- Time to first occurrence of stroke (fatal and non-fatal).(From randomisation (month 0) to end-of-study (up to 48 months).)
- Time to first occurrence of a composite MACE endpoint consisting of: all-cause mortality, non-fatal MI and non-fatal stroke(From randomisation (month 0) to end-of-study (up to 48 months).)
研究者
研究点 (2059)
Loading locations...
相似试验
进行中（未招募）
3 期
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationSystemic InflammationHeart FailureNCT06200207Novo Nordisk A/S680
招募中
3 期
Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammatiosystemische ontstekingenAtherosclerotic cardiovascular disease and chronic kidney disease1008220610038430NL-OMON54148ovo Nordisk120
招募中
3 期
Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammatioASCVD, CKD and systemic inflammationJPRN-jRCT2021210033Miyazaki Daisuke400
尚未招募
3 期
ARTEMIS - A research study to look at how ziltivekimab works compared to placeboin people with a heart attackCTRI/2024/06/068283ovo Nordisk A S
进行中（未招募）
1 期
ZEUS – A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammatioAtherosclerotic cardiovascular diseaseChronic kidney disease Systemic inflammationMedDRA version: 21.1Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 100000004866MedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.1Level: LLTClassification code 10067394Term: hs-CRP increasedSystem Organ Class: 100000004848MedDRA version: 21.0Level: LLTClassification code 10011418Term: CRP increasedSystem Organ Class: 100000004848EUCTR2020-004853-59-ESovo Nordisk A/S6,200
相关资讯
GSK's Efimosfermin Opens Two Phase 3 Trials Targeting MASH Cirrhosis, Signaling a Shift Toward Disease-Modifying Outcomes- GSK initiated two Phase 3 trials (NEBULA-1 and NEBULA-2) for efimosfermin alfa, an FGF21 analog, targeting compensated cirrhosis (fibrosis stage F4) due to MASH.
- NEBULA-1 plans to enroll 1,740 patients with a primary endpoint of time to first liver-related clinical composite outcome, while NEBULA-2 plans 380 patients assessing fibrosis improvement without MASH worsening at 96 weeks.
- The move signals a competitive shift in the MASH field from intermediate fibrosis stages toward cirrhosis, a population with no currently approved pharmacological treatment options.
- Efimosfermin holds FDA Breakthrough Therapy and EMA PRIME designations, with Phase 2 data showing 45.2% fibrosis improvement and 67.7% MASH resolution without worsening fibrosis.2 months agoIL-6 Modifies Coronary Artery Disease Risk Associated with Elevated Lipoprotein(a), UK Biobank Study Finds- A UK Biobank study of 43,512 participants found that IL-6 levels significantly modify the risk of incident coronary artery disease associated with elevated lipoprotein(a).
- Individuals with elevated Lp(a) (≥125 nmol/L) in the highest IL-6 quartile had a 43% increased CAD risk (HR, 1.43; 95% CI, 1.25-1.63), while those in the lowest IL-6 quartile showed no significant increase (HR, 1.09; 95% CI, 0.85-1.38; P for interaction = 0.008).
- The findings support IL-6 as an actionable inflammatory biomarker that may help identify patients with elevated Lp(a) who could benefit from targeted preventive strategies.
- No inflammatory biomarkers modified Lp(a)-associated risk for aortic valve stenosis, and the neutrophil-to-lymphocyte ratio interaction did not remain significant after multiple testing correction.2 months ago